AZ’s Brilinta reduced rate of stroke and death in high-risk subgroup
New analysis of prespecified subgroup comes from phase III THALES trial
Read More
Tag: Brilinta
US green lights AZ’s Brilinta to reduce risk of stroke
Approval is based on results from phase III THALES trial
Read More
AZ unveils detailed data from THALES trial
The results show a 17% cut in the risk of subsequent stroke in patients taking Brilinta and aspirin
Read More
US priority review for AZ’ Brilinta/aspirin combination
Brilinta/aspirin combo could be the first US-approved dual antiplatelet therapy to cut risk of second stroke
Read More
New US approval for AZ’ Brilinta
New Brilinta indication expands treatment to high-risk coronary patients without a history of stroke or heart attack
Read More
Brilinta reduces CV events but increases bleeding
The drug reduced the relative risk for the composite of cardiovascular death, heart attack, or stroke by 10% compared with aspirin alone.
Read More
Brilinta hits targets in PhIII cardiovascular/diabetes trial
AstraZeneca’s Brilinta has been found to reduce cardiovascular events in patients with coronary heart disease and diabetes but no prior heart attack or stroke.
Read More
AZ enrolls first patient in Brilinta stroke trial
Brilinta (ticagrelor) is approved for the treatment of acute coronary syndromes and prevention of further coronary events in patients at high-risk following a heart attack.
Read More
AZ books 3 percent sales drop for Q3
AstraZeneca has booked another sales decline for the third quarter but says the impact of generic competition is starting to wane.
Read More
Extended use of AZ’ Brilinta cuts CV death risk 29%
Long-term use of AstraZeneca’s Brilinta in patients with a history of heart attack reduces the risk of cardiovascular death by 29 percent, a new sub analysis of data from the Phase III PEGASUS-TIMI 54 trial has found.
Read More
AZ books 12 percent sales fall for Q4
AstraZeneca has booked a drop in revenues for the fourth quarter but says 2017 could be a ‘turning point’ for the firm as it comes to the end of its patent-expiry phase and begins its return to growth.
Read More
AZ’ Brilinta disappoints in arterial disease trial
AstraZeneca’s Brilinta has been hit with another setback after failing to show superiority over veteran bloodthinner clopidogrel in patients with peripheral arterial disease (PAD).
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
